ABBOTT INDIA LIMITED

The FDA cleared Medtronic's SmartGuard algorithm as an interoperable automated glycemic controller, enabling integration with Abbott's Instinct sensor for type 1 diabetes patients.

Entera Bio will present Phase 2 data for EB613, the first once-daily oral anabolic tablet for postmenopausal osteoporosis, showing rapid BMD increases at both cortical and cancellous bone sites.

Abbott received regulatory approval for Thailand's first denosumab biosimilar, making advanced osteoporosis and cancer-related bone loss therapy more affordable for an estimated 3 million affected Thais.

Quetzal Therapeutics officially launched with $50 million in committed capital to develop transformative therapies for rare and life-threatening diseases.

LogicFlo AI raised $2.7 million in seed funding led by Lightspeed to expand its AI agent platform across pharmaceutical, biotech, and medtech organizations globally.

Beta Bionics announced plans to integrate its iLet Bionic Pancreas automated insulin delivery system with Abbott's future dual glucose-ketone sensor in the U.S.

Abbott and MSD Pharmaceuticals have formed a strategic distribution partnership to expand access to MSD's oral anti-diabetic portfolio in India, including sitagliptin and its fixed-dose combinations.

Health Canada has approved Abbott's i-STAT TBI test cartridge for use with whole blood, enabling clinicians to assess suspected concussions at the patient's bedside with lab-quality results in 15 minutes.

Abbott received FDA approval for the Tendyne transcatheter mitral valve replacement system, marking the first device of its kind to replace mitral valves without open-heart surgery for patients with severe mitral annular calcification.

Abbott's FreeStyle Libre continuous glucose monitoring system is the first CGM shown to reduce cardiovascular complication severity in diabetes patients, with data showing a 78% reduction in heart-related hospitalizations for Type 1 diabetes patients.